Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Open accessThe DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Hypoxia and free radicals, such as reactive oxygen and nitrogen species, can alter the function and/or activity of the transcription factor hypoxia-inducible factor 1 (HIF1). Interplay between free radicals, hypoxia and HIF1 activity is complex and can influence the earliest stages of tumour development. The hypoxic environment of tumours is heterogeneous, both spatially and temporally, and can change in response to cytotoxic therapy. Free radicals created by hypoxia, hypoxia-reoxygenation cycling and immune cell infiltration after cytotoxic therapy strongly influence HIF1 activity. HIF1 can then promote endothelial and tumour cell survival. As discussed here, a constant theme emerges: inhibition of HIF1 activity will have therapeutic benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many human cancers contain regions of hypoxia because of rapid cell proliferation and the presence of intratumoral blood vessels that are structurally and functionally abnormal, resulting in both spatial and temporal heterogeneity of blood flow (1, 2).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“ROS production later stabilizes the HIF-1α protein and increases expression of HIF-1α and its target genes (Moeller et al., 2004;Dewhirst et al., 2008;Harada et al., 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Dewhirst et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L., & Hirota, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308197200 · Cited by 226
RetractedPlum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · cited 1×
“The HIF1α subunit is exquisitely regulated by hydroxylation of proline residues in its oxygen-dependent degradation domain (ODD) that target it for recognition by the von Hippel Lindau (VHL) complex and subsequent proteasomal degradation under aerobic condition”
BackgroundThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Origins of hypoxia in solid tumours The presence of hypoxia in tumours is a well-established source of resistance to radiation therapy and chemotherap”
Background
Cited by
Items 301–400 of 999
Epel, B., Kotecha, M., & Halpern, H. (2017) · Journal of magnetic resonance (San Diego, Calif. 1997 : Print) · doi:10.1016/j.jmr.2017.04.017 · Cited by 50
Membranous NOX5-derived ROS oxidizes and activates local Src to promote malignancy of tumor cells
Chen, J., Wang, Y., Zhang, W., Zhao, D., Zhang, L., Fan, J., Li, J., & Zhan, Q. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0193-z · Cited by 56
Dietary Energy Modulation and Autophagy: Exploiting Metabolic Vulnerabilities to Starve Cancer
Cozzo, A. J., Coleman, M. F., Pearce, J. B., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590192 · Cited by 56
Advances in nanoparticle-based radiotherapy for cancer treatment
He, M., Chen, S., Yu, H., Fan, X., Wu, H., Wang, Y., Wang, H., & Yin, X. (2024) · iScience · doi:10.1016/j.isci.2024.111602 · Cited by 71
Focus on the Controversial Aspects of 64Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
Colombié, M., Gouard, S., Frindel, M., Vidal, A., Chérel, M., Kraeber‐Bodéré, F., Rousseau, C., & Bourgeois, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00058 · Cited by 59
Cancer Stem Cells Under Hypoxia as a Chemoresistance Factor in the Breast and Brain
Crowder, S. W., Balikov, D. A., Hwang, Y., & Sung, H. (2014) · Current Pathobiology Reports · doi:10.1007/s40139-013-0035-6 · Cited by 59
On the Path to Seeking Novel Radiosensitizers
Katz, D., Ito, E., & Liu, F. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.002 · Cited by 63
Hsieh, C., Lin, Y., Wu, C., Lee, H., Shyu, W., & Wang, C.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0618 · Cited by 55
An Oxygen Self‐Evolving, Multistage Delivery System for Deeply Located Hypoxic Tumor Treatment
Jiang, W., Han, X., Zhang, T., Xie, D., Zhang, H., & Hu, Y. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901303 · Cited by 54
Targeting the Redox Landscape in Cancer Therapy
Narayanan, D., Ma, S., & Özcelik, D. (2020) · Cancers · doi:10.3390/cancers12071706 · Cited by 61
“This process is accompanied by blood vessel development, which is often devoid of coordinated structure and organization, and induces oxidative stress through periods of changing redox environment [16,18].”
“Double-Edged Sword” Effect of Reactive Oxygen Species (ROS) in Tumor Development and Carcinogenesis
Zhao, W., Zhuang, P., Chen, Y., Wu, Y. L., Zhong, M., & Lun, Y. (2023) · Physiological Research · doi:10.33549/physiolres.935007 · Cited by 65
Common Responses of Tumors and Wounds to Hypoxia
Payen, V. L., Brisson, L., Dewhirst, M. W., & Sonveaux, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000098 · Cited by 56
Self-citationHerrmann, A., Rice, M., Lévy, R., Pizer, B. L., Losty, P. D., Moss, D., & Sée, V. (2015) · Oncogenesis · doi:10.1038/oncsis.2014.52 · Cited by 55
Kim, H., Kasper, A. C., Moon, E. J., Park, Y., Wooten, C. M., Dewhirst, M. W., & Hong, J. (2008) · Organic Letters · doi:10.1021/ol8024617 · Cited by 53
Self-citationDatamining approaches for modeling tumor control probability
Naqa, I. E., Deasy, J. O., Mu, Y., Huang, E., Hope, A. J., Lindsay, P. E., Apte, A., Alaly, J., & Bradley, J. D. (2010) · Acta Oncologica · doi:10.3109/02841861003649224 · Cited by 53
Zhang, J., Lan, S., Liu, Q. R., Liu, J. M., & Chen, X. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083634 · Cited by 53
Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Alimoradi, H., Matikonda, S. S., Gamble, A. B., Giles, G. I., & Greish, K. F. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160217130049 · Cited by 57
3D modeling of cancer stem cell niche
He, J., Xiong, L., Li, Q., Lin, L., Miao, X., Yan, S., Hong, Z., Yang, L., Wen, Y., & Deng, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19847 · Cited by 65
Steingold, J. M., & Hatfield, S. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570041 · Cited by 234
Seo, K., Seo, S., Ki, S. H., & Shin, S. M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.014 · Cited by 55
Radiotherapy in Combination With Cytokine Treatment
Palata, O., Podzimkova, N., Nedvedova, E., Umprecht, A., Sadilkova, L. K., Jelinkova, L. P., Špíšek, R., & Adkins, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00367 · Cited by 55
Wang, B., Wang, X.-J., Kang, H., Bai, M., Guan, H., Wang, Z.-W., Zan, Y., Song, L., Min, W., Lin, S., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356648 · Cited by 54
Warner, A. B., Rabbani, Z. N., Hardee, M. E., Kim, S. J., Broadwater, G., Bentley, R. C., Snyder, S. A., Vujaskovic, Z., Oosterwijk, E., Harris, L. N., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.32 · Cited by 52
Self-citationShen, H. M., Cook, K. M., Gee, H. E., & Hau, E. K. C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01639-2 · Cited by 58
Wang, S., Cheng, M., Wang, S., Jiang, W., Yang, F., Shen, X., Zhang, L., Yan, X., Jiang, B., & Fan, K. (2024) · Advanced Materials · doi:10.1002/adma.202403921 · Cited by 77
Jiang, X., Lai, Y., Xia, W., Yang, W., Wang, J., Pan, J., Zhao, Q., Zhou, X., Li, S., Zhang, S., et al. (2025) · Advanced Materials · doi:10.1002/adma.202411869 · Cited by 71
Gottschald, O. R., Malec, V., Krasteva, G., Hasan, D., Kamlah, F., Herold, S., Rose, F., Seeger, W., & Hanze, J. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq032 · Cited by 48
Glioblastoma Stem Cells and Their Microenvironment
Sattiraju, A., Sai, K. K. S., & Mintz, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-69194-7_7 · Cited by 52
Tumour hypoxia in driving genomic instability and tumour evolution
Suvac, A., Ashton, J., & Bristow, R. G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00781-9 · Cited by 142
“This targets HIF1α for von Hippel Lindau (VHL)-dependent and E3 ubiquitin ligase-dependent ubiquitination and proteasomal degradation under normoxic conditions 2,3 .”
Starmans, M. H. W., Chu, K. C., Haider, S., Nguyen, F., Seigneuric, R., Magagnin, M. G., Koritzinsky, M., Kasprzyk, A., Boutros, P. C., Wouters, B. G., et al. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.02.002 · Cited by 50
Pre- and post-irradiation mild hyperthermia enabled by NIR-II for sensitizing radiotherapy
Li, Q., Hang, L., Jiang, W., Dou, J., Xiao, L., Tang, X., Yao, Y., & Wang, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120235 · Cited by 48
Ma, X., Liang, X., Yao, M., Gao, Y., Luo, Q., Li, X., Yu, Y., Sun, Y., Cheng, M. H. Y., Chen, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41782-w · Cited by 49
“Hypoxia is particularly closelyrelated to the RT ef fi cacy and is the major reason for the ineffectiveness of RT, as oxygen concentration directly in fl uences the generation of cytotoxic free radicals of radiation 32,33 .”
Olbryt, M., Habryka, A., Student, S., Jarząb, M., Tyszkiewicz, T., & Lisowska, K. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105104 · Cited by 53
Mandeville, H., Ng, Q. S., Daley, F. M., Barber, P. R., Pierce, G., Finch, J., Burke, M. M., Bell, A. G., Townsend, E. R., Kozarski, R., et al. (2012) · Radiology · doi:10.1148/radiol.12111505 · Cited by 50
Stromal uptake and transmission of acid is a pathway for venting cancer cell-generated acid
Hulikova, A., Black, N., Hsia, L.-T., Wilding, J., Bodmer, W. F., & Swietach, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610954113 · Cited by 47
Repeatability of tumour hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer
Silvoniemi, A., Suilamo, S., Laitinen, T., Forsback, S. J., Löyttyniemi, E., Vaittinen, S., Saunavaara, V., Solin, O. H., Grönroos, T. J., & Minn, H. R. I. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3857-3 · Cited by 51
Bischoff, P. L., Altmeyer, A., & Dumont, F. J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902824172 · Cited by 53
Photosynthetic Microorganisms Coupled Photodynamic Therapy for Enhanced Antitumor Immune Effect
Wang, H., Liu, H., Guo, Y., Zai, W., Li, X., Xiong, W., Zhao, X., Yao, Y., Hu, Y., Zou, Z., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.028 · Cited by 46
Dong, P. X., Hu, J., Yu, S., Zhou, Y., Shi, T., Zhao, Y., Wang, X., & Liu, X. (2021) · Small Methods · doi:10.1002/smtd.202100581 · Cited by 47
Tumor-colonizing bacteria: A potential tumor targeting therapy
Zu, C., & Wang, J. (2013) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.776511 · Cited by 50
The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia
Schaaf, M. B. E., Cojocari, D., Keulers, T. G., Jutten, B., Starmans, M. H. W., de Jong, M. C., Begg, A. C., Savelkouls, K. G. M., Bussink, J., Vooijs, M., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.015 · Cited by 52
Jutten, B., Keulers, T. G., Peeters, H. J. M., Schaaf, M. B. E., Savelkouls, K. G. M., Compter, I., Clarijs, R., Schijns, O. E. M. G., Ackermans, L. P. C. M., Teernstra, O., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1409926 · Cited by 47
Dünker, N., & Jendrossek, V. (2019) · Cancers · doi:10.3390/cancers11101499 · Cited by 62
Real-time measurement of tumour hypoxia using an implantable microfabricated oxygen sensor
Marland, J. R. K., Gray, M., Dunare, C. C., Blair, E. O., Tsiamis, A., Sullivan, P., González‐Fernández, E., Greenhalgh, S. N., Gregson, R., Clutton, R. E., et al. (2020) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2020.100375 · Cited by 54
Small-molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors
Werner, L. R., Huang, S., Francis, D. M., Armstrong, E. A., Ma, F., Li, C., Iyer, G., Canon, J., & Harari, P. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1056-t · Cited by 45
Emerging tale of UPR and cancer: an essentiality for malignancy
Hazari, Y., Bashir, A., Haq, E. U., & Fazili, K. M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5343-0 · Cited by 53
Famulla, S., Horrighs, A., Cramer, A., Sell, H., & Eckel, J. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.200 · Cited by 53
miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer
Quéro, L., Dubois, L. J., Lieuwes, N. G., Hennequin, C., & Lambin, P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.063 · Cited by 46
“Acute/cycling hypoxia has been described as a major source of therapy resistance [9–11].”
BackgroundCD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells
Maeda, K., Ding, Q., Yoshimitsu, M., Kuwahata, T., Miyazaki, Y., Tsukasa, K., Hayashi, T., Shinchi, H., Natsugoe, S., & Takao, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071025 · Cited by 54
Pulsed Electron Paramagnetic Resonance Imaging: Applications in the Studies of Tumor Physiology
Kishimoto, S., Matsumoto, K., Saito, K., Enomoto, A., Matsumoto, S., Mitchell, J. B., Devasahayam, N., & Krishna, M. C. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7391 · Cited by 46
Metabolic reprogramming by tobacco-specific nitrosamines (TSNAs) in cancer
Sarlak, S., Lalou, C., Amoêdo, N. D., & Rossignol, R. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.09.001 · Cited by 55
“Many lines of evidence indicate that levels of intracellular ROS were closely linked to HIF1 α stabilization, possibly through the modification of prolyl-hydroxylase (PHD) activity (147).”
Flexibility and Adaptation of Cancer Cells in a Heterogenous Metabolic Microenvironment
Bluemel, G., Mondal, A., & Leithner, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031476 · Cited by 52
Chaperone Mediated Autophagy Substrates and Components in Cancer
Ríos, J., Sequeida, Á., Albornoz, A., & Budini, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614677 · Cited by 48
Xu, G., Mak, E. C., & Lo, K. K. (2021) · Inorganic Chemistry Frontiers · doi:10.1039/d1qi00931a · Cited by 45
Considering the role of pyruvate in tumor cells during hypoxia
Roudier, E. A., & Perrin, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.02.003 · Cited by 52
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 46
Radiocurability Is Associated with Interstitial Fluid Pressure in Human Tumor Xenografts
Rofstad, E. K., Gaustad, J., Brurberg, K. G., Mathiesen, B. S., Galappathi, K., & Simonsen, T. G. (2009) · Neoplasia · doi:10.1593/neo.91152 · Cited by 47
Oxygen-sensing scaffolds for 3-dimensional cell and tissue culture
Jenkins, J., Dmitriev, R. I., Morten, K., McDermott, K. W. G., & Papkovsky, D. B. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.01.032 · Cited by 50
Gorr, T. A. (2016) · Acta Physiologica · doi:10.1111/apha.12747 · Cited by 54
Gutsche, K., Randi, E. B., Blank, V., Fink, D. A., Wenger, R. H., Leo, C., & Scholz, C. C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.002 · Cited by 51
Xu, T., & Xiao, D. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0480-2 · Cited by 44
Harnessing Tumor Microenvironment for Nanoparticle‐Mediated Radiotherapy
Zhu, S., Gu, Z., & Zhao, Y. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800050 · Cited by 44
Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging
Carmona-Bozo, J. C., Manavaki, R., Woitek, R., Torheim, T., Baxter, G. C., Caracò, C., Provenzano, E., Graves, M. J., Fryer, T. D., Patterson, A. J., et al. (2020) · European Radiology · doi:10.1007/s00330-020-07067-2 · Cited by 47
Daneau, G., Boidot, R., Martinive, P., & Feron, O. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0583 · Cited by 44
Martinive, P., Defresne, F., Quaghebeur, E., Daneau, G., Crokart, N., Grégoire, V., Gallez, B., Dessy, C., & Féron, O. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06798.x · Cited by 49
Kim, H.-J., Lee, H.-J., Jun, J.-I., Oh, Y., Choi, S.-G., Kim, H., Chung, C.-W., Kim, I., Park, I.-S., Chae, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903704106 · Cited by 43
Huh, J. W., Tanksley, J., Chino, J., Willett, C. G., & Dewhirst, M. W. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2744 · Cited by 47
Self-citationJiang, Z. L., He, L., Yu, X., Yang, Z., Wu, W., Wang, X., Mao, R., Cui, D., Chen, X. S., & Li, W. (2021) · ACS Nano · doi:10.1021/acsnano.1c01063 · Cited by 44
The Role of the Hypoxia-Related Unfolded Protein Response (UPR) in the Tumor Microenvironment
Bartoszewska, S., Collawn, J. F., & Bartoszewski, R. (2022) · Cancers · doi:10.3390/cancers14194870 · Cited by 43
X‐Ray‐Induced Drug Release for Cancer Therapy
Liu, H., Zhao, J. L., Xue, Y., Zhang, J., Bai, H., Pan, S., Peng, B., Li, L., & Voelcker, N. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202306100 · Cited by 48
Xiong, Y., Li, J., Jiang, X., Zhen, W., Ma, X., & Lin, W. (2025) · Advanced Science · doi:10.1002/advs.202413518 · Cited by 48
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
Foehrenbacher, A., Secomb, T. W., Wilson, W. R., & Hicks, K. O. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00314 · Cited by 43
Autophagy-Dependent Secretion: Contribution to Tumor Progression
Keulers, T. G., Schaaf, M. B. E., & Rouschop, K. M. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00251 · Cited by 46
Microfluidics in Malignant Glioma Research and Precision Medicine
Logun, M. T., Zhao, W., Mao, L., & Karumbaiah, L. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700221 · Cited by 48
Mimura, I., Tanaka, T., Wada, Y., Kodama, T., & Nangaku, M. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10r19fm · Cited by 42
Acellular implantable and injectable hydrogels for vascular regeneration
Blatchley, M. R., & Gerecht, S. (2015) · Biomedical Materials · doi:10.1088/1748-6041/10/3/034001 · Cited by 45
Molecular Imaging of Tumor Hypoxia with Positron Emission Tomography
Kelada, O. J., & Carlson, D. J. (2014) · Radiation Research · doi:10.1667/rr13590.1 · Cited by 46
Ikezawa, Y., Sakakibara‐Konishi, J., Mizugaki, H., Oizumi, S., & Nishimura, M. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1031-8 · Cited by 43
Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer
Grkovski, M., Lee, N. Y., Schöder, H. M., Carlin, S. D., Beattie, B. J., Riaz, N., Leeman, J. E., O’Donoghue, J. A., & Humm, J. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3720-6 · Cited by 44
Targeting the redox imbalance in mitochondria: A novel mode for cancer therapy
Mani, S., Swargiary, G., & Ralph, S. J. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.11.002 · Cited by 45
Prospective Application of Ferroptosis in Hypoxic Cells for Tumor Radiotherapy
Su, J., Zhao, Q., Zheng, Z., Wang, H., Bian, C., Meng, L., Xin, Y., & Jiang, X. M. (2022) · Antioxidants · doi:10.3390/antiox11050921 · Cited by 48
Tumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum
Taniguchi, S., Shimatani, Y., & Fujimori, M. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3515-4_5 · Cited by 41
Azobenzene‐Based Linker Strategy for Selective Activation of Antibody–Drug Conjugates
Xiao, D., Liu, L., Xie, F., Dong, J., Wang, Y., Xu, X., Zhong, W., Deng, H., Zhou, X., & Li, S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202310318 · Cited by 48
Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases.
Cannito, S., Paternostro, C., Busletta, C., Bocca, C., Colombatto, S., Miglietta, A., Novo, E., & Parola, M. (2014) · PubMed · doi:10.14670/hh-29.33 · Cited by 48
Impacts of Ionizing Radiation on the Different Compartments of the Tumor Microenvironment
Leroi, N., Lallemand, F., Coucke, P. A., Noël, A., & Martinive, P. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00078 · Cited by 47
Minimum dose rate estimation for pulsed FLASH radiotherapy: A dimensional analysis
Zhou, S., Zheng, D., Fan, Q., Yan, Y., Wang, S., Lei, Y., Besemer, A. E., Zhou, C., & Enke, C. A. (2020) · Medical Physics · doi:10.1002/mp.14181 · Cited by 42
Research Progress in Bioinspired Drug Delivery Systems
Tong, Q., Qiu, N., Ji, J., Ye, L., & Zhai, G. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1783235 · Cited by 42
Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review
Plazy, C., Hannani, D., & Gobbini, É. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01241-z · Cited by 47
Cao, J., He, L., Lin, G., Hu, C., Dong, R., Zhang, J., Zhu, H., Hu, Y., Wagner, C. R., He, Q., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.002 · Cited by 44
Kheshtchin, N., & Hadjati, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30643 · Cited by 44
Acute and chronic in vivo therapeutic resistance
Teicher, B. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.006 · Cited by 43
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K., & Secomb, T. W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126044 · Cited by 41
“Spatial and temporal variation in tumor hypoxia (5) may contribute to the heterogeneity in treatment response to precision oncology drug combinations (1).”
Self-citationClinical and Pre-clinical Methods for Quantifying Tumor Hypoxia
Rickard, A. G., Palmer, G. M., & Dewhirst, M. W. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_2 · Cited by 44
Self-citationChen, F., Chu, L., Li, J., Shi, Y., Xu, B., Gu, J., Yao, X., Tian, M., Yang, X., & Sun, X. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13295 · Cited by 39
Therapeutic Modification of Hypoxia
Horsman, M. R., Sørensen, B. S., Busk, M., & Siemann, D. W. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.08.014 · Cited by 41
Torregrosa, C., Chorin, F., Beltran, E. E. M., Neuzillet, C., & Cardot‐Ruffino, V. (2022) · Cancers · doi:10.3390/cancers14215402 · Cited by 55
Coutelle, O., Schiffmann, L. M., Liwschitz, M., Brunold, M., Goede, V., Hallek, M. J., Kashkar, H., & Hacker, U. T. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.629 · Cited by 44
Liu, Q., Palmgren, V. A. C., Danen, E. H. J., & Dévédec, S. E. L. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07802-6 · Cited by 48
Chitneni, S. K., Bida, G. T., Yuan, H., Palmer, G. M., Hay, M. P., Melcher, T., Wilson, W. R., Zalutsky, M. R., & Dewhirst, M. W. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.116293 · Cited by 43
Self-citationMolecular radiation biology: Perspectives for radiation oncology
Rodemann, H. P. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.08.023 · Cited by 40
Metadata
- Authors
- Dewhirst, M. W., Cao, Y., & Moeller, B.
- Affiliations
- Duke Medical Center (US)
- Corresponding author
- Dewhirst, Mark W.
- Venue
- Nature Reviews Cancer
- Published
- 2008-06
- Volume
- 8
- Issue
- 6
- Pages
- 425-437
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3943205
- OpenAlex
- W2016861891
- Cited by
- 1,022
- References
- 161
- Citations by year
- 2026: 27 · 2025: 29 · 2024: 30 · 2023: 52 · 2022: 60 · 2021: 70 · 2020: 76 · 2019: 44 · 2018: 64 · 2017: 53 · 2016: 73 · 2015: 65 · 2014: 63 · 2013: 63 · 2012: 62
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Update notices
- erratum (2008-07-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA40355, R01CA040355, P50CA068438)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Keywords
- tumor hypoxia, free radicals, reactive oxygen species, reactive nitrogen species, HIF-1, tumor angiogenesis, radiotherapy response, tumor heterogeneity, immune cell infiltration, tumor cell survival, endothelial cells
- MeSH terms
- Animals, Free Radicals, Humans, Neoplasms, Neovascularization, Pathologic, Nitric Oxide, Oxygen, Cell Hypoxia, Vascular Endothelial Growth Factor A, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.